Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 2, 2007, Pages 228-236

  Dunkelmann, Simone ^a   Kuenstner, Hubertus ^a   Nabavi, Elham ^a   Rohde, Bettina ^a   Groth, Peter ^a   Schuemichen, Carl ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Antithyroid drugs; Graves' disease; Radioiodine kinetics; Therapeutic efficacy; Thiamazole

Indexed keywords

RADIOACTIVE IODINE; THIAMAZOLE;

ADULT; AGED; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; FOLLOW UP; GRAVES DISEASE; HORMONE SYNTHESIS; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; RADIATION DOSE DISTRIBUTION; RADIATION PROTECTION; THYROID GLAND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; METHIMAZOLE; MIDDLE AGED; RADIOPHARMACEUTICALS; THYROID GLAND; TREATMENT OUTCOME;

EID: 33846444762     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0234-z     Document Type: Article

References (35)

1. Urbannek V, Voth E, Moka D, Schicha H. Radioiodine therapy of Graves' disease dosimetric comparison of different strategies concerning antithyroid drugs. Nuklearmedizin 2001;40:111-5.
2. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999;9(12):1181-8.
3. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999;84(4):1229-33.
4. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001;86(8):3488-93.
5. 131I ablation for Graves' disease. J Clin Endocrinol Metab 2001;86(7):3016-21.
6. 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun 2004;25(7):675-82.
7. Connell JM, Hilditch TE, Robertson J, Coghill G, Alexander WD. Radioprotective action of carbimazole in radioiodine therapy for thyrotoxicosis - influence of the drug on iodine kinetics. Eur J Nucl Med 1987;13(7):358-61.
8. Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 2006;33:730-7.
9. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetry of the lobe of the thyroid gland by means of realtime sonography. Dtsch Med Wochenschr 1981;106:1338-40.
10. Dunkelmann S, Neumann V, Staub U, Kuenstner H, Groth P, Schümichen C. Results of a risk-adapted and functional radioiodine therapy in Graves' disease. Nuklearmedizin 2005;44:238-42.
11. Rink T, Bormuth FJ, Braun S, Zimny M, Schroth H-J. Concept and validation of a simple model of the intrathyroidal iodine kinetics. Nuklearmedizin 2004;43:21-5.
12. 99mTc-pertechnetate in 19 hyperthyroid cats. Vet Radiol Ultrasound 2005;46(3):267-72.
13. Suzuki K, Lavaroni S, Mori A, Ohta M, Saito J, Pietrarelli M, et al. Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci U S A 1998;95(14):8251-6.
14. - symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab 1997;82(10):3331-6.
15. Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Weetmann AP. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf) 1998;49(4):517-23.
16. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999;9(8):821-3.
17. Ferreira AC, Lima LP, Araujo RL, Muller G, Rocha RP, Rosenthal D. Rapid regulation of thyroid sodium-iodide symporter by thyrotrophin and iodide. J Endocrinol 2005;184:69-76.
18. Clerc J, Kahn E, Fragu P. SIMS evidence that carbimazole enhances spatial heterogeneity of thyroid iodine storage and targeting in a woman with Graves' disease. Cell Mol Biol (Noisy-le-grand) 2001;47(3):519-27.
19. Walter MA, Christ-Crain M, Müller B, Müller-Brand J. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication. Nuklearmedizin 2005;44:33-6.
20. Nakashima T, Taurog A. Rapid conversion of carbimazole to methimazole in serum: evidence for an enzymatic mechanism. Clin Endocrinol (Oxf) 1979;10(6):637-48.
21. Schneider P, Körber C, Körber-Hafner N, Hänscheid H, Reiners C. Does an individual estimation of half-life improve the results of radioiodine therapy of Graves' disease? Nuklearmedizin 2002;41(6):240-4.
22. Bockisch A, Jarnitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993;34:1632-8.
23. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F. Treatment with lithium prevents serum thyroid hormone increase after withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2002;87:4490-5.
24. Groth P, Dunkelmann S, Staub U, Schümichen C. Stunning der Schilddrüse - ein Früheffekt der Iod-131-Therapie? Nuklearmedizin 2005;44:A103.
25. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 2002;12(2):135-9.
26. Hancock LD, Tuttle RM, Le Mar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997;47(4):425-30.
27. Imseis RE, Vanmiddelesworth L, Massie JD, Bush AJ, Vanmiddelesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83:685-7.
28. 131I therapy of hyperthyroid disease: effect on cure rate evaluated by a randomised clinical trial. J Clin Endocrinol Metab 2004;89(9):4439-44.
29. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthioracil in the induction of euthyroidism. Clin Endocrinol 2001;54:385-90.
30. Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid 1995;5(1):7-12.
31. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131-iodine activity. Results from a prospective, randomised, multicentre study. Eur J Clin Invest 1995;25(3):186-93.
32. Greig WR, Crooks J, Macgregor AG, Mcinthosh JA. The radioprotective effect of methylthiouracil on the thyroid gland of the rat. Br J Radiol 1965;38:72-4.
33. Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf) 2003;59(3):321-7.
34. 131I-therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87(3):1073-7.
35. Marcocci C, Gianchechi D, Masini I, Golia F, Ceccarelli C, Bracci E, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990;13(6):513-20.